ClinicalTrials.gg
CompletedNCT04956432Updated Jan 24, 2025

A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout

A Phase 3 interventional study of SHR4640 and Allopurinol in Gout, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
779
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. — none open to participants now, none under way, none of them phase 3. Gout · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
Largest of 11
779 · median 50
Started
2021
the only one that year
Phase 3
4 of 11
none open now
Registered
7th of 11
by date

Among the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd., this one has the largest enrollment, is the only one that started in 2021, is one of 4 in phase 3, and was the 7th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

None of the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. is open now. The open studies under Gout, anywhere →

Where they have run

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Gout by Jiangsu HengRui Medicine Co., Ltd. as a file.
02

Study summary

This study will assess the serum uric acid lowering effects and safety of SHR4640 compared to Allopurinol in subjects with gout.

03

Conditions studied

  • Gout

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject who met 1977 or 2015 ACR (American College of Rheumatology) classification of Gout and has a serum acid ≥ 480 μmol/L at screening; 2、18 kg/m2 ≤ (BMI) ≤ 35 kg/m2.

Exclusion criteria

Exclusion Criteria:

  1. Subject who is pregnant or breastfeeding;
  2. or Aspartate aminotransferase or total >1.5 upper normal limit;
  3. Subject with a positive test for HLA-B*5801;
  4. Estimated (MDRD formula) \<60ml/min;
  5. ≥8%;
  6. Subject with known or allergy to SHR4640 and allopurinol, or any component of SHR4640;
  7. Subject with kidney stones or suspicion of kidney stones;
  8. Subject who has acute gout flares within 2 weeks before randomization;
  9. Subject with a history of within the previous 5 years;
  10. Subject with a history of active peptic ulcer within a year;
  11. Subject with a history of xanthine urine.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
779 participants (actual)

Study arms

  • Experimental
    Treatment group A

    SHR4640+Allopurinol Placebo;once a day, orally, for 52 weeks

    Drug: SHR4640

  • Active comparator
    Treatment group B

    Allopurinol+ SHR4640 Placebo;once a day, orally, for 52 weeks.

    Drug: Allopurinol

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with a serum uric acid level≤360 μmol/L

    Time frame: Start of Treatment to end of study (approximately 16 weeks)

Secondary outcomes

  1. Percentage change in serum uric acid from baseline at each visit during 16 weeks of treatment

    Time frame: Start of Treatment to end of study (approximately 16 weeks)

  2. Absolute changes in serum uric acid from baseline at each visit during 16 weeks of treatment

    Time frame: Start of Treatment to end of study (approximately 16 weeks)

  3. The proportion of subjects with A serum uric acid level≤ 360 μmol/L at each visit within 16 weeks of treatment

    Time frame: Start of Treatment to end of study (approximately 16 weeks)

  4. Percentage change of serum uric acid from baseline at each visit within 52 weeks of treatment

    Time frame: Start of Treatment to end of study (approximately 52 weeks)

  5. change value of serum uric acid from baseline at each visit within 52 weeks of treatment

    Time frame: Start of Treatment to end of study (approximately 52 weeks)

  6. proportion of subjects with serum uric acid ≤ 360 μmol/L at each visit within 52 weeks of treatment

    Time frame: Start of Treatment to end of study (approximately 52 weeks)

  7. serum uric acid value at each visit within 52 weeks of treatment

    Time frame: Start of Treatment to end of study (approximately 52 weeks)

07

Study locations

1 site
  • RenJi Hospital, Shanghai JiaoTong University School Of Medicine
    Shanghai, Shanghai 200127, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Dec 2023, 29 months.

Of 21 phase 3 interventional studies under Gout, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 25. This study's 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2021
First posted
Jul 9, 2021
StartActual
Jun 15, 2021
Primary completionActual
Dec 13, 2023
CompletionActual
Aug 23, 2024
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04956432
Responsible party
Sponsor
First posted
Jul 9, 2021
Start date
Jun 15, 2021
Primary completion
Dec 13, 2023
Completion
Aug 23, 2024
Last update
Jan 24, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruzinurad

Start the discussion